Improving Risk Stratification in Hypertrophic Cardiomyopathy: A Novel Score Combining Echocardiography, Clinical, and Medication Data

Improving Risk Stratification in Hypertrophic Cardiomyopathy: A Novel Score Combining Echocardiography, Clinical, and Medication Data | Signal Canvas | ScienceToStartup

Page Freshness

Signal Canvas proof surface

Canonical route: /signal-canvas/improving-risk-stratification-in-hypertrophic-cardiomyopathy-a-novel-score-combining-echocardiography-clinical-and-medic

stale

Proof freshness: stale
Proof status: unverified
Display score: 7/10
Last proof check: 2026-03-30
Score updated: 2026-04-02
Score fresh until: 2026-05-02
References: 48
Source count: 3
Coverage: 50%

This page is showing the last landed evidence receipt and score bundle because the latest proof data is outside the freshness window.

Agent Handoff

Canonical ID improving-risk-stratification-in-hypertrophic-cardiomyopathy-a-novel-score-combining-echocardiography-clinical-and-medic | Route /signal-canvas/improving-risk-stratification-in-hypertrophic-cardiomyopathy-a-novel-score-combining-echocardiography-clinical-and-medic

REST example

curl https://sciencetostartup.com/api/v1/agent-handoff/signal-canvas/improving-risk-stratification-in-hypertrophic-cardiomyopathy-a-novel-score-combining-echocardiography-clinical-and-medic

MCP example

{
  "tool": "search_signal_canvas",
  "arguments": {
    "mode": "paper",
    "paper_ref": "improving-risk-stratification-in-hypertrophic-cardiomyopathy-a-novel-score-combining-echocardiography-clinical-and-medic",
    "query_text": "Summarize Improving Risk Stratification in Hypertrophic Cardiomyopathy: A Novel Score Combining Echocardiography, Clinical, and Medication Data"
  }
}

source_context

{
  "surface": "signal_canvas",
  "mode": "paper",
  "query": "Improving Risk Stratification in Hypertrophic Cardiomyopathy: A Novel Score Combining Echocardiography, Clinical, and Medication Data",
  "normalized_query": "2603.26254",
  "route": "/signal-canvas/improving-risk-stratification-in-hypertrophic-cardiomyopathy-a-novel-score-combining-echocardiography-clinical-and-medic",
  "paper_ref": "improving-risk-stratification-in-hypertrophic-cardiomyopathy-a-novel-score-combining-echocardiography-clinical-and-medic",
  "topic_slug": null,
  "benchmark_ref": null,
  "dataset_ref": null
}

Evidence Receipt

Route status: building

Claims: 8

References: 48

Proof: Verification pending

Freshness state: computing

Source paper: Improving Risk Stratification in Hypertrophic Cardiomyopathy: A Novel Score Combining Echocardiography, Clinical, and Medication Data

PDF: https://arxiv.org/pdf/2603.26254v1

Source count: 3

Coverage: 50%

Last proof check: 2026-03-30T21:54:11.564Z

Signal Canvas receipt window

Watch and verify: Improving Risk Stratification in Hypertrophic Cardiomyopathy: A Novel Score Combining Echocardiography, Clinical, and Medication Data

/buildability/improving-risk-stratification-in-hypertrophic-cardiomyopathy-a-novel-score-combining-echocardiography-clinical-and-medic

Watchwatch

Subject: Improving Risk Stratification in Hypertrophic Cardiomyopathy: A Novel Score Combining Echocardiography, Clinical, and Medication Data

Verdict

Preparing verified analysis

GitHub Code Pulse

No public code linked for this paper yet.

Claim map

Strong 8Mixed 0Weak 0

Evidencepartial
This study develops a robust, explainable machine learning (ML) risk score leveraging routinely collected echocardiographic, clinical, and medication data, typically contained within Electronic Health Records (EHRs), to predict a 5-year composite cardiovascular outcome in HCM patients.
Implicationpartial
This is explicitly stated in the abstract as the primary goal of the study.
Verificationpartial
partial
Evidencepartial
The final Random Forest ensemble model achieved a high internal Area Under the Curve (AUC) of 0.85 +- 0.02, significantly outperforming the ESC score (0.56 +- 0.03).
Implicationpartial
This specific performance metric is directly reported in the abstract with a standard deviation.
Verificationpartial
partial
Evidencepartial
The final Random Forest ensemble model achieved a high internal Area Under the Curve (AUC) of 0.85 +- 0.02, significantly outperforming the ESC score (0.56 +- 0.03).
Implicationpartial
The abstract directly compares the AUC of the ML score to the ESC score and states it is significantly outperforming.
Verificationpartial
partial
Evidencepartial
Critically, survival curve analysis on the external validation set showed superior risk separation for the ML score (Log-rank p = 8.62 x 10^(-4) compared to the ESC score (p = 0.0559).
Implicationpartial
The abstract provides specific statistical evidence (Log-rank p-values) to support this claim of superior risk separation.
Verificationpartial
partial
Evidencepartial
Furthermore, longitudinal analyses demonstrate that the proposed risk score remains stable over time in event-free patients.
Implicationpartial
This is explicitly stated in the abstract as a finding from longitudinal analyses.
Verificationpartial
partial
Evidencepartial
This study develops a robust, explainable machine learning (ML) risk score leveraging routinely collected echocardiographic, clinical, and medication data, typically contained within Electronic Health Records (EHRs), to predict a 5-year composite cardiovascular outcome in HCM patients.
Implicationpartial
The abstract clearly outlines the data sources used for the ML model.
Verificationpartial
partial
Evidencepartial
The model was trained and internally validated using a large cohort (N=1,201) from the SHARE registry (Florence Hospital) and externally validated on an independent cohort (N=382) from Rennes Hospital.
Implicationpartial
The abstract specifies the sizes of the cohorts used for internal and external validation.
Verificationpartial
partial
Evidencepartial
However, such approaches were either basically static, providing only a baseline risk, or relied on imaging modalities like CMR that are not universally accessible in routine workflows (Table I).
Implicationpartial
The abstract contrasts the current study's approach with prior work, highlighting these limitations.
Verificationpartial
partial

Author intelligence and commercialization panels stay hidden until the proof receipt is verified, cites at least 3 references, includes at least 2 sources, and clears 50% coverage. The paper narrative and citation surfaces remain public while verification is pending.

Improving Risk Stratification in Hypertrophic Cardiomyopathy: A Novel Score Combining Echocardiography, Clinical, and Medication Data

Use Signal Canvas as the narrative proof surface

Use this Signal Canvas via API or MCP

Signal Canvas proof surface